ORENCIA
As listed in the register: ORENCIA 125 mg, solution injectable en seringue préremplie
125 mg · solution injectable
- Prescription only
- Active substance
- Abatacept
- Made by
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (ORENCIA). It describes the substance, not this exact product.
Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28.
This interaction provides a costimulatory signal necessary for full activation of T lymphocytes.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-13
Safety of the active substance
From the US prescribing label for the same active substance (ORENCIA). It describes the substance, not this exact product.
Most common adverse events (≥10%) in RA are headache, upper respiratory tract infection, nasopharyngitis, and nausea.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain2 matching products
CanadaNo exact match for this strength and form
Details
| Made by | BRISTOL-MYERS SQUIBB PHARMA (IRLANDE) |
|---|---|
| Active substance | Abatacept |
| Strength | 125 mg |
| Form | solution injectable |
| Route | sous-cutanée |
| Dispensing (as stated by the register) | prescription réservée aux spécialistes et services PEDIATRIE · prescription réservée aux spécialistes et services MEDECINE INTERNE · prescription réservée aux spécialistes et services RHUMATOLOGIE · prescription réservée aux spécialistes et services DERMATOLOGIE · liste I |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/07/389 |
| Name in the register | ORENCIA 125 mg, solution injectable en seringue préremplie |
| Packs | 4 seringue(s) préremplie(s) en verre de 1 ml avec aiguille(s) acier avec protège-aiguille |
| CIS | 69256710 |
| CIP13 | 3400926884376 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
5 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution injectable4 products
- 50 mg
- 87,5 mg
125 mg2
125 mg · 2 companies
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE) · this page
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- poudre pour solution à diluer pour perfusion1 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.